Holen Sie sich die Stockscreener-App
13.44
2.82%
-0.39
Handel nachbörslich:
13.20
-0.24
-1.79%
Schlusskurs vom Vortag:
$13.83
Offen:
$13.63
24-Stunden-Volumen:
1.76M
Relative Volume:
1.18
Marktkapitalisierung:
$1.95B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-4.7158
EPS:
-2.85
Netto-Cashflow:
$-402.10M
1W Leistung:
-1.68%
1M Leistung:
-3.66%
6M Leistung:
-42.32%
1J Leistung:
-42.39%
1-Tages-Spanne:
$13.25
$14.02
1-Wochen-Bereich:
$13.25
$14.71
52-Wochen-Spanne:
$10.57
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8547
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Vergleichen Sie DNLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
13.44 | 2.01B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-01-03 | Eingeleitet | William Blair | Outperform |
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Does Denali Therapeutics Inc. stock perform well during market downturnsPost Market Picks With Low Risk - jammulinksnews.com
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy - Insider Monkey
What makes Denali Therapeutics Inc. stock price move sharplyTop Growth Planner For Every Investor - jammulinksnews.com
What is Denali Therapeutics Inc. company’s growth strategyFree Stock Insights For Every Investor - jammulinksnews.com
Price momentum metrics for Denali Therapeutics Inc. explainedStock Portfolio Allocation Guidance for Volatile Markets - metal.it
11 Best Future Stocks to Buy Now - Insider Monkey
Can Denali Therapeutics Inc. Rally Enough to Break EvenReal Profit Trade Plan Suggestions Shared Widely - metal.it
Is Denali Therapeutics Inc. a growth stock or a value stockBest Dividend Data Feed Backed By Experts - jammulinksnews.com
Volume Surge May Signal Institutional Interest in Denali Therapeutics Inc.Trade Setups With Clear Risk Limits Highlighted - metal.it
What are analysts’ price targets for Denali Therapeutics Inc. in the next 12 monthsMaximize returns with expert trading insights - jammulinksnews.com
Is it the right time to buy Denali Therapeutics Inc. stockAccess powerful market insights for free - jammulinksnews.com
What are the technical indicators suggesting about Denali Therapeutics Inc.Real Time Guidance For 2025 - jammulinksnews.com
How volatile is Denali Therapeutics Inc. stock compared to the marketGet exclusive market analysis for investors - jammulinksnews.com
How does Denali Therapeutics Inc. generate profit in a changing economyUnlock powerful stock screening tools today - jammulinksnews.com
Published on: 2025-07-28 03:16:35 - jammulinksnews.com
Is Denali Therapeutics Inc. stock overvalued or undervaluedMaximize gains with data-driven stock picks - jammulinksnews.com
What is the risk reward ratio of investing in Denali Therapeutics Inc. stockBoost your returns with professional guidance - jammulinksnews.com
How strong is Denali Therapeutics Inc. company’s balance sheetCapitalize on market momentum for maximum profit - jammulinksnews.com
Published on: 2025-07-27 16:21:55 - jammulinksnews.com
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - MSN
What drives Denali Therapeutics Inc. stock priceRapid growth opportunities - PrintWeekIndia
Why Denali Therapeutics Inc. stock is on top investor watchlistsStrongest growth potential - jammulinksnews.com
Will Denali Therapeutics Inc. stock benefit from interest rate changesFree Investment Community - jammulinksnews.com
What analysts say about Denali Therapeutics Inc. stockOutstanding capital growth - Autocar Professional
Is Denali Therapeutics Inc. a good long term investmentOutperformance with explosive growth - jammulinksnews.com
Denali Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - jammulinksnews.com
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Denali Therapeutics Inc-Aktie (DNLI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Watts Ryan J. | President and CEO |
Jul 09 '25 |
Sale |
15.00 |
495,282 |
7,429,230 |
253,071 |
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):